These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32336840)

  • 1. Chapter 8 Paramyxoviruses.
    Perspect Med Virol; 1985; 1():345-404. PubMed ID: 32336840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior infection by respiratory syncytial virus or parainfluenza viruses augments virus-specific IgG responses induced by the measles/mumps/rubella vaccine.
    Ziola B; Karvonen B; Stewart J
    Viral Immunol; 1994; 7(4):205-14. PubMed ID: 7576035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.
    Wendt CH; Hertz MI
    Semin Respir Infect; 1995 Dec; 10(4):224-31. PubMed ID: 8668850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination against acute respiratory virus infections and measles in man.
    Osterhaus AD; de Vries P
    Immunobiology; 1992 Feb; 184(2-3):180-92. PubMed ID: 1587542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae.
    Cooney MK; Fox JP; Hall CE
    Am J Epidemiol; 1975 Jun; 101(6):532-51. PubMed ID: 168766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact.
    Sørup S; Benn CS; Stensballe LG; Aaby P; Ravn H
    Vaccine; 2015 Jan; 33(1):237-45. PubMed ID: 25446818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development.
    Crowe JE
    Vaccine; 1995 Mar; 13(4):415-21. PubMed ID: 7793140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing Papaverine as an Antiviral Agent against Influenza Viruses and Paramyxoviruses.
    Aggarwal M; Leser GP; Lamb RA
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31896588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for measles, mumps and rubella in children.
    Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational use of measles, mumps and rubella (MMR) vaccine.
    Carter H; Campbell H
    Drugs; 1993 May; 45(5):677-83. PubMed ID: 7686463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles and mumps immunization: benefit versus risk factors.
    Krugman S
    Dev Biol Stand; 1979; 43():253-7. PubMed ID: 520672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles, mumps and rubella: control by vaccination.
    van Druten JA; de Boo T; Plantinga AD
    Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.